Abstract
Lebrikizumab (LEB) was studied for treating immune mediated disorders, including asthma and atopic dermatitis. LAVOLTA I (NCT01867125) and II (NCT01868061) (LI&LII) were duplicate randomized, placebo-controlled Phase 3 LEB trials in uncontrolled asthma that enrolled subjects irrespective of asthma exacerbation history, baseline blood eosinophilia, or FeNO. LI&II failed to show consistently significant results in asthma exacerbation rate reduction. Here, effects of LEB on inflammatory biomarkers were assessed in patients with asthma.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call